SEB Investment Management wishes to inform investors that we will move portfolio management of our healthcare and biotechnology funds to another team in the fund management company as of 1 February 2021. Angelica Fatouros, who is part of the entity fundamental equities, will be portfolio manager for the funds.
Fatouros has extensive experience as pharmaceutical analyst and portfolio manager and has a PhD in pharmaceuticals. The funds will be managed based on a fundamental investment process where, among other things, analysis of the companies’ management and business model are key elements. Previously, the fund was managed based on a quantitative investment process.
The following funds/sub funds and all their share classes are affected:
|SEB Concept Biotechnology
||SEB Fund 3 – SEB Medical Fund
C (EUR), ISIN LU0385485148
D (EUR), ISIN LU0118405827
UC (EUR), ISIN LU2249630927
D (USD), ISIN LU0047324214
UD (USD), ISIN LU2249630331
Past performance does not guarantee future performance. The value of investment funds and other financial instruments may rise as well as fall and there is no guarantee you will recover your original investment. Key investor information documents and prospectuses are available on www.sebgroup.lu/funds.